M. Ercis, Idil Tarikogullari, Vanessa K. Pazdernik, Maria L Gonzalez Suarez, R. Baweja, Alessandro Miola, Osama A. Abulseoud, Jonathan G. Leung, Susan L. McElroy, A. Cuellar-Barboza, M. Gitlin, A. Ozerdem, Mark A. Frye, Balwinder Singh
2026.2.27BIPOLAR DISORDERS
tlooto Summary
Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) have shown promise in improving renal outcomes in patients with and without diabetes, but their effect on lithium‐associated kidney dysfunction remains unknown.
Abstract
Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i), initially developed for type 2 diabetes, have shown promise in improving renal outcomes in patients with and without diabetes. However, their effect on lithium‐associated kidney dysfunction remains unknown.
Citation format
ERCIS, M., et al. SGLT2 inhibitors associated with improved kidney function in lithium-treated patients with mood disorders: A real-world historical cohort study. BIPOLAR DISORDERS, 2026, 28(2): e70094-e70094.